Unlocking AAV Gene Therapy Cost Of Goods Savings With dbDNA™: A Comparative Analysis With Plasmid DNA

This analysis explores how a switch from conventional plasmid DNA to a cell‑free, enzymatically produced DNA format can significantly lower the cost of goods for AAV gene therapy manufacturing. High required doses and complex production workflows make AAV therapies expensive, with DNA representing a major cost driver. Traditional plasmid production involves lengthy bacterial fermentation, scalability challenges, and risks such as bacterial impurities and sequence mutations. In contrast, enzymatically produced DNA can be generated more rapidly, with higher purity, fewer contaminants, and no reliance on fermentation steps. Studies show it can reduce DNA requirements for transfection by up to 40%, improve capsid quality, and streamline upstream processing. Economic modeling demonstrates baseline cost reductions of around 14% per dose, with potential savings exceeding 20% when transfection parameters are optimized, translating to millions of dollars saved annually. These efficiencies support more affordable, scalable AAV manufacturing across the entire product lifecycle.